Specialised Therapeutics Asia will partner with CTTQ-Akeso to commercialise a new immuno-oncology therapy in Australia, Singapore and across Southeast Asia.
- Welcome to Specialised Therapeutics
-
SE Asia
+65 3158 9940
-
1300 798 820
-
New Zealand
+64 9801 0299
SidebarCategory - Specialised Therapeutics - Page 3
April 12, 2023
March 22, 2023
Cholangiocarcinoma: Understanding This Rare Liver Disease
This article is contributed by Dr Choo Su Pin, a senior medical oncologist at Curie Oncology who specialises in gastrointestinal cancers.
March 15, 2023
Thailand Office Opened
Specialised Therapeutics is thrilled to announce the official opening of its Thailand office, as we continue our mission to provide specialist therapies to patients across South East Asia. We are determined to ensure our medicines reach as many eligible patients as possible – particularly in oncology, with almost 200,000 Thai residents diagnosed with cancer every year (*Globocan 2020).
March 9, 2023
International Women’s Day 2023
ST Medical Director Paula Fenwick knew from a young age in South Africa that a career in science beckoned. But there were no scientists in her family and her parents were initially reluctant to let her attend university. Her godmother stepped in and helped her blaze a trail that has taken her around the world and allowed her to mentor other young women seeking a STEM career. To mark #IWD23, Paula reflects on her career journey.
March 8, 2023
International Women’s Day 2023
Born and raised in cities throughout North India, 28-year-old Prakriti Langer arrived in Australia five years ago to pursue a Masters in Biotechnology. After graduating, “I knew I wanted to gain global exposure. I chose Australia, which is a thriving hub for life sciences.”
February 17, 2023
Global Sarcoma Therapy Now Approved for New Zealand Patients
Singapore and Auckland, New Zealand, 17 February 2023: Independent biopharmaceutical company Specialised Therapeutics (ST) is pleased to announce that its portfolio therapy to treat rare soft tissue sarcomas has now been approved in New Zealand.
January 20, 2023
Pharma Dispatch: 20 January, 2023
Pharma Dispatch 20 January 2023 New Zealand Approval for Specialised Therapeutics’ Cancer Therapy Specialised Therapeutics Asia has announced that its therapy to treat rare gastrointestinal stromal tumours, QINLOCK (ripretinib), has been approved for use in New Zealand and will now be considered for funding by PHARMAC. The regulator, Medsafe, has approved QINLOCK for
January 20, 2023
New Therapy to Treat Rare Gastrointestinal Stromal Tumour Approved for New Zealand Patients
Singapore and New Zealand, 20 January 2023: Independent biopharmaceutical company Specialised Therapeutics Asia (ST) is pleased to announce that a new therapy to treat rare gastrointestinal stromal tumour (GIST) shown to improve survival has now been approved in New Zealand.
January 20, 2023
Pharma in Focus: 20 January, 2023
PHARMA IN FOCUS By Tiffany Walker 20 January 2023 ST Notches Another Win Specialised Therapeutics (ST) has scored approval for Qinlock in New Zealand, marking the second of five regions that the company has rights to commercialise the advanced gastrointestinal stromal tumour (GIST) treatment. The Singapore headquartered company was established to commercialise new therapies and
October 12, 2022
National Medicines Policy Review 2022
ST has made several key recommendations to the Federal Government’s National Medicines Policy Review, to improve timely and affordable access to specialist medicines. Click to read full submission.